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Essential Role of the E3 Ubiquitin Ligase Cbl-b
in T Cell Anergy Induction
antigen, generation of regulatory T cells, and T cell an-
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1 diabetes (Yokoi et al., 2002).sion of self-reactive T cells involved in autoimmune
Here, we report that Cbl-b is selectively induced dur-diseases. Here, we show that the E3 ubiquitin ligase
ing the early phase of T cell unresponsiveness. Cbl-b/Cbl-b is upregulated in T cells after tolerizing signals.
T cells are largely resistant to T cell anergy inductionLoss of Cbl-b in mice results in impaired induction of
both in vitro and in vivo. Importantly, in vivo, the pres-T cell tolerance both in vitro and in vivo. Importantly,
ence of Cbl-b determines whether mice die or surviverechallenge of Cbl-b mutant mice with the tolerizing
after challenge with the same antigen. The results iden-antigen results in massive lethality. Moreover, ablation
tify an essential role of the E3 ligase Cbl-b in the regula-of Cbl-b resulted in exacerbated autoimmunity. Mech-
tion of clonal T cell anergy.anistically, loss of Cbl-b rescues reduced calcium mo-
bilization of anergic T cells, which was attributed to
Cbl-b-mediated regulation of PLC-1 phosphoryla- Results
tion. Our results show a critical role for Cbl-b in the
regulation of peripheral tolerance and anergy of T cells. Cbl-b Controls T Cell Unresponsiveness In Vitro
T cell clonal anergy is a growth arrest state in which cell
proliferation is greatly impaired in a number of differentIntroduction
ways (Schwartz, 2003). We first investigated whether
Cbl-b is indeed involved in ionomycin-induced func-Peripheral mature T cells play a critical role in mounting
immune responses against invading pathogens through tional T cell anergy, a model system previously used to
mimic early events of T cell tolerance (Macian et al.,the engagement of the T cell antigen receptor (TCR)
with antigenic peptides presented by the major histo- 2002). As reported previously, wild-type T cells did not
proliferate after ionomycin-treatment as compared tocompatibility complex molecules (MHCs) on antigen-
presenting cells (APCs) and, at the same time, are toler- control cells upon restimulation (Figure 1A). Surprisingly,
Cbl-b/ T cells displayed no or only a slight reductionant to self-antigens. The induction of peripheral T cell
tolerance involves a variety of mechanisms, including in proliferation when low concentrations of ionomycin
were used. Similarly, the levels of IL-2 were markedlythe deletion of self-reactive T cells, ignorance of self-
reduced in ionomycin-treated wild-type T cells, whereas
IL-2 production remained much higher in Cbl-b/T cells*Correspondence: yuncail@liai.org (Y.-C.L.); josef.penninger@imba.
even when the concentration of ionomycin reached 400oeaw.ac.at (J.M.P.)
7 These authors contributed equally to this work. ng per ml (Figure 1B). To test whether Cbl-b is a true
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Figure 1. A Role of Cbl-b in T Cell Anergy
In Vitro
(A) Activated CD4 T cells from the lymph
nodes of Cbl-b/ and Cbl-b/ mice were
cultured in the absence or the presence of
different concentrations of ionomycin (Iono)
for 16 hr. Cells were washed and restimulated
with anti-CD3 and anti-CD28. Proliferation
was measured after 48 hr by 3H-thymidine in-
corporation.
(B) Supernatants from the cultured cells as
in (A) were collected and measured for IL-2
production by ELISA.
(C) CD4 T cells as in (A) were pretreated
with low to high doses of ionomycin and 3H-
thymidine incorporation was measured. The
proliferative response is shown as percent-
age of proliferation. Values from cells without
ionomycin treatment were considered as
100%. Data in (A) to (C) are representative of
three repeated experiments.
(D) Cbl-b induction in ionomycin-treated
T cells. Purified CD4 T cells from OT-II trans-
genic mice were cultured with OVA peptide
and irradiated splenic cells for 5 days and
then incubated with indicated doses of iono-
mycin (Iono) for 16 hr. Cell lysates were
probed with antibodies as indicated. The in-
tensity of PLC-1 band was quantified by Bio-
Rad Quantity One software and normalized. 0 nM ionomycin treatment was considered to be basal level (1.0). The relative Cbl-b protein
expression levels from lanes 1–5 are: 1.0, 1.4, 1.6, 2.2, and 3.0, respectively.
mediator of anergy induction, we next examined the findings (Heissmeyer et al., 2004; Wells et al., 2003),
ionomycin-treated anergic wild-type T cells showed al-proliferative responses by using very high concentrations
most no Ca2 mobilization upon TCR/CD3 crosslinkingof ionomycin. At the highest concentration of ionomycin
compared to untreated control T cells (Figure 2A). How-(1.5 g/ml), wild-type T cells showed 90% reduction in
ever, Cbl-b/ T cells were largely resistant to iono-proliferation (Figure 1C), whereas the Cbl-b/ T cells
mycin-induced effects on calcium mobilization. Theseshowed only 40% reduction; i.e., the proliferative re-
results suggest that a Ca2-dependent pathway is atsponse of Cbl-b/ T cells remained strong even at the
least one of the mechanisms by which Cbl-b mediateshighest concentration of ionomycin. However, other fac-
T cell anergy.tors must also be capable of inducing the anergic state.
The reduced Ca2 influx in anergic T cell promptedIn an antigen-induced anergy model in the absence
us to investigate whether TCR stimulation of ionomycin-of CD28 costimulation, we found that Cbl-b expression
treated T cells affects PLC-1, which controls Ca2is induced both in the levels of mRNA and protein (data
mobilization in T cells. Anti-CD3 stimulation of iono-not shown). We then examined Cbl-b expression in
mycin-pretreated T cells caused only a little or even noT cells rendered unresponsive through ionomycin treat-
downmodulation of PLC-1 as compared to control cellsment. Treatment of T cells under anergizing culture con-
(Figure 2B). Intriguingly, the amount of the phosphory-ditions by using ionomycin alone triggered increased
lated form of PLC-1 markedly decreased upon anti-Cbl-b expression (Figure 1D). In addition, the ionomycin-
CD3 stimulation in ionomycin-treated wild-type T cellsinduced Cbl-b expression was specific, since the protein
as compared to nonstimulated T cells. The reducedlevels of PLC-1, PKC, Akt, or the adaptor protein Grb2,
phosphorylation of PLC-1 in wild-type anergic T cellsdid not show obvious alterations (Figure 1D). These data
was not observed in Cbl-b/ T cells under anergy-in-show that expression levels of the E3 ligase Cbl-b are
ducing conditions (Figure 2C). Notably, an increasedselectively increased in anergized T cells in response
phosphorylation of PLC-1 was observed in Cbl-b/to ionomycin treatment. Importantly, our data show that
T cells in ionomycin-untreated cells. In both wild-type andablation of Cbl-b results in impaired induction of iono-
Cbl-b/ T cells, anti-CD3-induced Akt phosphorylationmycin-induced T cell tolerance.
was similar between untreated and ionomycin-treated
cells. The phosphorylation of PLC-1 remained at in-
Cbl-b Regulates PLC-1 Phosphorylation creased levels in Cbl-b/ T cells even when very high
in Anergic T Cells concentrations of ionomycin were used (Figure 2D).
One of the characteristics of ionomycin- or antibody- Since we used Cbl-b/ T cells from two different mutant
induced T cell anergy is the reduced calcium mobiliza- mouse lines (Bachmaier et al., 2000; Chiang et al., 2000)
tion upon restimulation with anti-CD3 (Heissmeyer et for the present study, it was important to compare
al., 2004; Wells et al., 2003). To gain molecular insights PLC-1 phosphorylation in the anergic T cell from both
into Cbl-b-regulated T cell anergy, we examined whether types of mutant mouse lines by using higher concentra-
tions of ionomycin. Cbl-b/ T cells isolated from bothCbl-b affects calcium signaling. Consistent with recent
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Figure 2. Cbl-b Controls PLC-1 Phosphorylation in Anergic T Cells
(A) Activated CD4 T cells from wild-type or Cbl-b/ mice were left untreated (control) or treated with ionomycin (Iono) for 16 hr and loaded
with Indo-1. Cells were incubated with anti-CD3, and Ca2 release was initiated by crosslinking with secondary rabbit anti-hamster Ab (RH,
arrow). Ionomycin (open arrow) was added to control for viability.
(B) Activated CD4 T cells from wild-type mice were left untreated or treated with ionomycin as in (A). T cells were then stimulated with anti-
CD3 for 3 min and cell lysates probed with phosphospecific antibodies against PLC-1 (p-PLC-1) or Akt (p-Akt). Membranes were reprobed
with Abs to PLC-1 and Akt to control for loading.
(C) Purified CD4 T cells from wild-type (/) and Cbl-b deficient mice (/) were cultured without or with ionomycin (100 ng/ml). T cells
were stimulated with anti-CD3 for 10 min and cell lysates probed with Abs as indicated. Grb2 was used as a loading control.
(D) CD4 T cells from control (/) and Cbl-b/ (/) mice were treated with different concentrations of ionomycin, washed, and then
stimulated with anti-CD3 for 10 min. Phosphorylation of PLC-1 was examined by using anti-phospho-PLC-1 Abs. Cell lysates were probed
with anti-PLC-1 and anti-Grb2 Abs.
(E and F) Comparison of phosphorylation of PLC-1 in ionomycin-induced anergic Cbl-b/ T cells isolated from two different Cbl-b mutant
mouse lines ([E]  Cbl-b/ mice generated by Chiang et al. 2000; [F]  Cbl-b/ mice generated by Bachmaier et al. 2000). In both mouse
lines we observed the same PLC-1 phosphorylation phenotypes. Blots were probed for Cbl-b to show Cbl-b induction and absence of Cbl-b
protein in both mutant mouse lines.
(G) Purified naive CD4 T cells from wild-type (/) and Cbl-b/ (/) mice were stimulated with anti-CD3 plus anti-CD28 and cell lysates
blotted with Abs as indicated. To detect the phosphorylation of Vav1, lysates were subjected to anti-Vav1 immunoprecipitation and subsequent
blotting with anti-phosphotyrosine Abs followed by reprobing with anti-Vav1. PLC-1 phosphorylation was determined as above.
(H) Purified CD4 T cells from wild-type (/) and Cbl-b/ (/) mice were cultured for 2 days in the presence of anti-CD3 plus anti-CD28
(effector CD4 T cells). Cells were then rested, and restimulated with anti-CD3 and anti-CD28. Lysates were analyzed as in (G).
(I) Jurkat T cells were transfected with PLC-1, Xpress-Cbl-b and HA-Ub plasmids. Transfected cells were left untreated or stimulated with
anti-CD3 for 15 min. Cell lysates were immunoprecipitated with anti-PLC-1 and blotted with anti-HA. Membranes were then reprobed with
PLC-1. Total cell lysates were blotted with anti-Xpress to reveal Xpress-Cbl-b. (Ub)n-PLC-1 indicates polyubiquitinated PLC-1.
(J) Purified CD4 T cells from Cbl-b/ and Cbl-b/ mice were stimulated and then pretreated with ionomycin as in (A). The cells were then
stimulated with anti-CD3 plus anti-CD28 and subjected to immunoprecipitation with anti-PLC-1. Immunoprecipitates were blotted with anti-
Ub antibody and membranes reprobed with anti-PLC-1.
lines displayed a rescue in the reduced PLC-1 phos- ylation (Bachmaier et al., 2000; Chiang et al., 2000). To
test whether the increased phosphorylation of PLC-1phorylation induced by ionomycin treatment, even at a
concentration of 1.5 g/ml (Figures 2E and 2F). Thus, in Cbl-b/ T cells is unique in previously stimulated
T cells, we directly compared the phosphorylation ofin two different genetically mutant lines, Cbl-b controls
PLC1 phosphorylation in ionomycin-induced T cell these two proteins in naı¨ve versus activated T cells.
Consistent with our previous observation, the phosphor-tolerance.
We and others have previously shown that in freshly ylation of Vav1, but not PLC-1, was increased in naive
Cbl-b/ T cells (Figure 2G). Tyrosine phosphorylationisolated T cells Cbl-b deficiency does not affect tyrosine
phosphorylation of PLC-1 but controls Vav1 phosphor- of PLC-1 was augmented in activated Cbl-b/ T cells
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upon restimulation, whereas the tyrosine phosphoryla- tide results in expansion of antigen-specific P14 T cells
followed by deletion of the activated cells (Figure 4Ation of Vav1 was not further altered in activated T cells
as compared to naive T cells (Figure 2H). Thus, the and Kyburz et al., 1993). Repeated injection of P14 TCR
transgenic mice with the p33 antigen leads to peptide-regulation of PLC-1 and calcium mobilization by Cbl-b
appears to be distinct in naive versus activated T cells. specific T cell anergy defined by impaired proliferation
and IL-2 production to rechallenge with the p33 peptide.We next examined whether Cbl-b can act as an E3
ligase for PLC-1. Transient Cbl-b overexpression in The T cell tolerance phenotype can be first detected
around day 4 (Figure 4B). Addition of IL-2 reverses theJurkat cells increased PLC-1 ubiquitination that de-
pended on TCR stimulation (Figure 2I). More importantly, proliferative defect of in vivo tolerized P14 TCR trans-
genic cells (Figure 4B). Importantly, whereas Cbl-b ex-after ionomycin-treatment, anti-CD3 stimulation induced
Ub conjugation to PLC-1 in wild-type T cells, whereas pression was low in activated T cells on day 2 after the
initial injection, Cbl-b protein expression was increasedthe PLC-1 ubiquitination in Cbl-b/ T cells was sub-
stantially reduced (Figure 2J). Taken together, these in anergized T cells after a second p33 challenge (Fig-
ure 4C).data indicate that induction of T cell tolerance results in
increased Cbl-b expression and subsequently impaired Injection of p33 into Cbl-b/ mice resulted in in-
creased in vivo expansion of Cbl-b/ P14 T cells afterPLC-1 activation and calcium mobilization. Loss of
Cbl-b prevents this impaired PLC1 activation and the first peptide injection (Figure 4D). This increased
in vivo response paralleled increased in vitro responsesrestores calcium influx. Moreover, Cbl-b can directly
regulate ubiquitination of endogenous PLC-1 in T cells of naive Cbl-b/ P14 T cells to the cognate p33 antigen
(Figure 4E). However, although Cbl-b/ P14 T cellsafter antigen receptor engagement.
showed increased expansion on day 2 after the first p33
injection, rechallenge of P14 TCR expressing cells inAdoptive Transfer of OVA-Tolerized CD4 T Cells
a Cbl-b-deficient mouse background did not result inTo examine the relevance of Cbl-b in the T cell tolerance,
increased proliferation in vitro (Figure 4F). Importantly,we employed an adoptive transfer experiment by using
the kinetics of deletion of activated T cells was compara-OT-II TCR transgenic mice (Bansal-Pakala et al., 2001;
ble between Cbl-b/ and Cbl-b/ mice (Figure 4D).Kearney et al., 1994). OT-II transgenic mice recognize
Intriguingly, whereas control T cells display peptide-an OVA peptide in the context of MHC class II (Barnden
specific anergy after the second p33 injection, in vivoet al., 1998). Loss of Cbl-b had no apparent effect on
antigen rechallenge of P14 TCR-expressing cells in adevelopment and selection of OT-II TCR transgenic thy-
Cbl-b-deficient mouse background did not induce T cellmocytes or the numbers and surface receptor expres-
anergy; Cbl-b/ P14 T cells still proliferated ex vivo tosion of mature OT-II T cells (not shown).
the cognate antigen p33 but did not respond to theCbl-b/ and Cbl-b/ OT-II transgenic mice were first
wrong peptide AV. The in vitro response of Cbl-b/ P14injected with high dose of soluble OVA peptide to induce
T cells also occurred at low antigen doses (range 0.1–5T cell tolerance or with PBS as control. CFSE-labeled
g/ml) and at different time points of analyses (days 4,CD4 T cells from these mice were then transferred into
7, and 8) (Figures 4G–4I). Since Cbl-b/ P14 T cellssyngeneic recipients followed by immunization with OVA
exhibited increased expansion to the initial p33 injec-peptide in CFA (Figure 3A). Both wild-type and Cbl-b/
tion, it was possible that we had “hyperactivated” theseT cells from PBS-treated mice proliferated in response
cells; however, even three challenges (days 0, 3, and 6)to OVA peptide challenge. OVA-tolerized wild-type
of Cbl-b/ P14 mice with low doses of p33 (0.1 g perT cells failed to divide in the recipient. However, Cbl-b/
mouse per injection) could not induce anergy in Cbl-b/T cells from OVA-tolerized mice displayed cell prolifera-
P14 T cells. Thus, loss of Cbl-b in CD8 P14 TCR trans-tion after antigen restimulation. Wild-type T cells from
genic T cells prevents the induction of T cell toleranceOVA-tolerized mice showed also a marked reduction in
to their cognate peptide antigen in vivo.IL-2 concentration, accompanied by decreased in vitro
proliferation (Figure 3B). Notably, the reduced cell prolif-
eration and IL-2 production were again rescued in Increased Mortality of Cbl-b/ Mice
Cbl-b/ OVA-tolerized T cells. These data show that upon p33 Antigen Rechallenge
Cbl-b controls the induction of antigen-specific CD4 Intriguingly, whereas all Cbl-b expressing P14 TCR
T cell tolerance. transgenic mice survived a second challenge with the
cognate p33 antigen on day 3, over 50% of Cbl-b/
P14 TCR transgenic mice died within hours after a sec-Cbl-b Controls T Cell Anergy Induction
in CD8 P14 Transgenic Mice ond p33 peptide challenge. Only four out of 41 Cbl-b/
P14 mice survived a third challenge with p33 (FigureTo evaluate whether Cbl-b was also relevant for anergy
induction of cytotoxic CD8 T cells in vivo, we crossed 5A). Even at low doses of in vivo restimulation, i.e., varia-
tion of the p33 dose at the third p33 injection, this lethalCbl-b/ mice (Bachmaier et al., 2000) with mice that
carry the P14 TCRV2V	8.2 transgene (Pircher et al., phenotype was frequently observed. Challenge of Cbl-b/
P14 TCR transgenic mice with the wrong antigen AV or1989). The P14 TCR recognizes the LCMV p33 peptide
presented by MHC class I. P14 TCR expressing cells the low-affinity peptide A4Y, a moderate agonist relative
to p33 (Sebzda et al., 1996) did not result in any detect-do not respond to the “wrong” peptide (AV), which also
binds to the same MHC class I molecule. Loss of Cbl-b able in vivo T cell responses or lethality (Figure 5A),
indicating that the response was p33 peptide specific.had no apparent effect on development and selection
of P14 TCR transgenic thymocytes or the numbers and Mutant mice developed massive edemas of multiple tis-
sues including the liver, lung, and intestine and diedsurface receptor expression of mature P14 T cells (not
shown). Intravenous injection of the cognate p33 pep- most likely due to respiratory and cardiovascular failure
Cbl-b in T Cell Tolerance
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Figure 3. Cbl-b Controls Anergy Induction of
CD4 OT-II T Cells
(A) Cbl-b/ and Cbl-b/ OT-II transgenic
mice were tolerized with high doses of solu-
ble OVA peptide or with PBS as control. CD4
T cells (V	5Thy1.2) purified from those mice
were labeled with CFSE and adoptively trans-
ferred into syngeneic Thy1.1 mice. The recipi-
ents were immunized with peptide in CFA.
Three days later, CFSE/V	5 T cells were an-
alyzed by FACS.
(B) CD4 T cells from the recipients as in (A)
were restimulated in vitro by incubating with
OVA peptide plus irradiated APCs and the
intracellular IL-2 concentration as well as pro-
liferation (as determined by CFSE) were mea-
sured by FACS.
(Figure 5B). We also generated Cbl-b/ P14 mice on a suggesting that loss of Cbl-b releases “anergized”
T cells from their defective cytokine production in vivo.Rag2/ background. In these mice, not a single Cbl-b/
Rag2/ P14 Tg mouse (n  9) survived the second p33 Increased cytokine levels were also detectable after ad-
justment to CD8 P14 T cell numbers (Figures 6B–6D).challenge on day 3, presumably due to the larger numbers
of P14 TCR Tg cells in such mice. Moreover, organ dam- These increased cytokine levels were only observed
after the in vivo p33 rechallenge on day 3, indicatingage was also more severe in Cbl-b/Rag2/ P14 mice
when compared to Cbl-b/Rag2/ P14 mice. that this cytokine storm was triggered by the cognate
antigen (Figures 6B–6D). Which one of these cytokinesAt the time of the in vivo rechallenge on day 3 or day 6
and at days 4, 5, and 8, we did not observe any apparent is the main mediator of death needs to be determined.
Thus, expression of the E3 ligase Cbl-b is essential todifferences in antigen receptor levels or expression of
surface molecules such as CD28, CD8, CD4, CD44, induce in vivo tolerance of peptide-specific T cells, and
expression of Cbl-b determines whether animals surviveCD62L, or CD69 between Cbl-b-expressing and Cbl-b
mutant P14 T cells. By contrast, transient induction of or die due to toxic T cell activation in response to re-
peated antigenic challenge.CD25 expression was markedly increased in Cbl-b/
P14 T cells, suggesting that anergized T cells display
selective activation defects in vivo. Since we observed Regulation of SEB-Induced Tolerance by Cbl-b
T cells recognize antigens as peptides in the groovea defect in CD25 upregulation, we analyzed cytokine
expression levels in vivo following p33 immunization. of MHCs or as superantigens (Kotzin et al., 1993). To
examine whether, in addition to peptide-specific CD8As compared to Cbl-b/ P14 mice, Cbl-b/ P14 mice
produced large amounts of serum IFN, TNF, and IL-2 and CD4 T cells, Cbl-b has also a role in superantigen-
induced tolerance (Kawabe and Ochi, 1990; Rellahanafter in vivo rechallenge with p33 on day 3 (Figure 6A),
Immunity
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Figure 4. Loss of Cbl-b Prevents Induction of Peptide-Specific In Vivo Tolerance of CD8 T Cells
(A) Typical expansion and deletion curve of wild-type CD8 P14 Tg splenic T cells. The time points of intravenous p33 peptide injections are
indicated. Mean values of four mice per group are shown.
(B) Splenic T cells were isolated from wild-type mice on day 2 and day 4 after p33 peptide injection (i.v., see scheme in [A]) and restimulated
in vitro with APCs loaded with the wrong peptide AV or the high-affinity peptide p33 (106 M).
(C) Western blot for Cbl-b and c-Cbl expression in T cells isolated from wild-type mice on day 2 (activated) and day 4 (anergic) after p33
injection. Data from individual mice are shown.
(D) Typical expansion and deletion curve of Cbl-b/ and Cbl-b/ CD8 P14 Tg splenic T cells after p33 peptide injections on days 0 and 3.
Mean values of at least four mice per group are shown.
(E–I) Splenic T cells were isolated from P14 Cbl-b/ and P14 Cbl-b/ mice on day 0 (nonimmunized mice), and day 2 (activated), day 4, day
7, and day 8 after p33 peptide injection on day 0, day 3, and day 6 (i.v., see scheme in [A]). Cells were restimulated in vitro with APCs loaded
with the wrong peptide AV or the high-affinity peptide p33 (106 M). Addition of murine rIL-2 (10 Units/ml) rescues the anergic phenotype in
Cbl-b expressing T cells. Data are representative of at least five different experiments.
et al., 1990), we crossed Cbl-b/ mice onto an H2d injection (not shown) or 25 days after the primary injec-
tion (Figure 6E), and such SEB reactivated Cbl-b/background and challenged these mice with the bacte-
rial superantigen staphylococcal enterotoxin B (SEB), T cells produced enhanced amounts of cytokines (Fig-
ure 6F). Importantly, whereas none of the Cbl-b express-a causative agent of food poisoning and toxic shock
syndrome. Similar to the peptide challenge, the initial ing mice showed morbidity in response to a second SEB
injection, five out of eight Cbl-b/ mice died withinexpansion of SEB reactive CD4 T cells was increased
in Cbl-b/ mice, but both Cbl-b/ and Cbl-b/ T cells hours after the SEB rechallenge on day 6. Thus, Cbl-b
is a critical molecule involved in in vivo immunotolerancedisplayed similar kinetics and extents of activation-
induced T cell deletion (Figure 6E). Cbl-b/ mice were to peptide- as well as superantigens.
tolerant to SEB and did not display apparent CD4 T cell
responses after a second in vivo challenge with SEB. Increased Incidence of Autoimmune Arthritis
To extend our tolerance studies to in vivo autoimmunity,By contrast, CD4 T cells from Cbl-b/ mice could be
reactivated to expand in vivo 6 days after the primary we backcrossed the Cbl-b mutation onto DBA/1 mice
Cbl-b in T Cell Tolerance
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Figure 5. Repeated Peptide Challenge Results in Death of P14 Cbl-b/ Mice
(A) Lethality/survival table. Mouse genotypes, mouse numbers, and percentages of survival are indicated. All mice were injected with the
indicated peptides or PBS as a vehicle control on day 0, day 3, and day 6. Lethality occurred in all instances within 24 hr after the in vivo rechal-
lenge.
(B) Macroscopic images of lungs (top, arrows) and intestines (bottom, arrows) of P14 Cbl-b/ and P14 Cbl-b/ mice after a second p33
challenge on day 3. P14 Cbl-b/ mice display labored breathing followed by irregular breathing near death. At necropsy lungs were filled
with fluid. We observed massive capillary dilation and hemorrhaging. All morbid mice have spider veins in their skin and flushed skin. Arrows
show lungs (top) and intestines (bottom). Li  livers.
for six to eight generations. Cbl-b/and Cbl-b/DBA/1 ited synovial hyperplasia and erosion of cartilage and
bone (Figure 7C). By contrast, the joints of Cbl-b/littermates were immunized with collagen emulsified in
complete Freund’s adjuvant (CFA). 21 days later, immu- DBA/1 mice did not display any apparent changes in
the morphology of the synovia, the cartilage, and thenized mice were boosted with collagen in mineral oil
only containing incomplete Freund’s adjuvant (IFA). By bone, findings that are consistent with the failure to
develop arthritis in Cbl-b/ DBA/1 mice. In addition,day 32 after the first injection, about 50% of Cbl-b/
DBA/1 mice developed arthritis, whereas almost 100% we observed marked increases in the collagen-specific
IgG2a production at day 27 in Cbl-b/ DBA/1 mice asof Cbl-b/ DBA/1 mice were arthritic, with a few mice
showing sign of arthritis before the second booster (Fig- compared with Cbl-b/ DBA/1 mice after immunization
with collagen in IFA (Figure 7D). Thus, ablation of Cbl-bure 7A). Cbl-b/ DBA/1 mice also displayed markedly
more severe joint inflammation, with earlier appearance exacerbates autoimmune arthritis even in the absence
of mycobacterial adjuvant. These results provide novelof paw swelling and concurrent occurrence of both fore-
limb and hindlimb thickening as compared to their experimental evidence that Cbl-b is a critical negative
regulator of antigen-induced arthritis induction in vivo.Cbl-b/ DBA/1 littermates.
The first injection of collagen with IFA does not induce
arthritis development in DBA/1 mice (Germann et al., Discussion
1995). The increased incidence of arthritis in Cbl-b/
DBA/1 mice prompted us to investigate whether Cbl-b Multiple mechanisms of T cell immunotolerance have
been reported, such as deletion of autoreactive T cellsdeficiency can overcome the requirement of CFA coin-
jection. Intriguingly, immunization with collagen-IFA in in the thymus and peripheral lymphoid organs or the
control of T cell activation by regulatory T cells (Schwartz,the initial phase caused a late onset of arthritis in
Cbl-b/ DBA/1 mice, with 50% of the mice suffering 2003). Moreover, it has been observed that antigen re-
ceptor stimulation in the absence of appropriate costim-from arthritis at day 40 (Figure 7B). By day 50, all Cbl-b/
DBA/1 mice developed arthritis. In contrast, none of the ulation results in T cell anergy. However, the molecular
mechanisms of stimulation-dependent T cell anergy areCbl-b/ DBA/1 littermates showed any disease signs
at any time point. At day 43 after immunization with largely unknown. Cbl-b is of particular interest since in
naive T cells loss of Cbl-b uncouples TCR stimulationcollagen in IFA, joints from Cbl-b/ DBA/1 mice exhib-
Immunity
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Figure 6. Cbl-b Controls In Vivo Tolerance
(A) In vivo serum cytokine levels in P14 Cbl-b/ and P14 Cbl-b/ mice measured at 8–16 hr after the second p33 (5 g/ml) injection. TNF,
IFN, and IL-2 serum levels were determined by ELISA. For IFN it should be noted that the detected serum levels were at the upper detection
limit of our ELISA assay indicating that the “real” values are much higher. Data from individual mice are shown.
(B–D) Kinetics of cytokine serum levels in P14 Cbl-b/ and P14 Cbl-b/ mice immunized with p33 (5 g/ml) on day 0 and day 3. In these
panels cytokine levels were adjusted to the relative numbers of CD8 P14 T cells in each mouse to exclude a bias in cell numbers. Cytokine
serum levels immediately after the p33 injection were not determined, and cytokine levels in P14 Cbl-b/ mice could only be followed until
day 4 due to the massive lethality in response to the second p33 injection. TNF, IFN, and IL-2 serum levels were determined by ELISA.
Data from individual mice are shown.
(E) Cbl-b controls SEB-induced tolerance in vivo. Expansion and deletion curves of TCRV	8 CD4 Cbl-b/ and TCRV	8 CD4 Cbl-b/
T cells in response to SEB (20 g). The time points of SEB injections on days 0 and 25 are indicated. Data from individual mice are shown.
Data are representative of three different experiments.
(F) In vivo serum cytokine levels in Cbl-b/ and Cbl-b/ mice measured at 8–16 hr after a second SEB (20 g) injection on day 6. TNF
levels were determined by ELISA. Data from individual mice are shown.
from the requirements of CD28 costimulation for effec- autoimmunity; that is, Cbl-b is selectively induced in
tolerizing conditions and Cbl-b expression is essentialtive proliferation and IL-2 production (Bachmaier et al.,
2000; Chiang et al., 2000). Cbl-b/ and c-Cbl/Cbl-b/ for antigen-receptor specific induction of immunotoler-
ance in vivo.double mutant mice develop spontaneous multiorgan
autoimmunity and display increased susceptibility to Based on our results we propose that Cbl-b regulates
the autoimmune response via participating in the pro-EAE, vasculitis, and arthritis induction (Bachmaier et
al., 2000; Chiang et al., 2000; Krawczyk et al., 2000; cess of T cell unresponsiveness. Since cbl-b/ T cells
can be still anergized at high doses of ionomycin, albeitNaramura et al., 2002; and the current study). Moreover,
Cbl-b has been recently identified as a type I diabetes less efficiently, other factors must also be capable of
inducing the anergic state. Earlier studies showed thatsusceptibility gene in rats (Yokoi et al., 2002), indicating
that Cbl-b is a critical autoimmunity gene. Our results anergic T cells display altered levels of protein tyrosine
phosphorylation (Bhandoola et al., 1993; Cho et al.,provide a molecular framework for the role of Cbl-b in
Cbl-b in T Cell Tolerance
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Figure 7. Collagen-Induced Arthritis in Cbl-b/ DBA/1 Mice
(A) Cbl-b/ or Cbl-b/ DBA/1 mice were immunized with collagen in CFA on day 0 and boosted with collagen in IFA on day 21. Ten Cbl-b/
and 8 Cbl-b/ DBA/1 mice were used. Incidence of arthritis (left) and severity of joint inflammation (right) were scored.
(B) Cbl-b/ (n  8) and Cbl-b/ (n  7) DBA/1 mice were immunized with collagen in IFA in the first and the second injections and monitored
for the incidence (left) and severity of arthritis (right).
(C) At day 43 after immunization with collagen in IFA (as in B), mice were sacrificed and joints removed for histological examination with
crystal violet staining. Joints from Cbl-b/ mice showed erosion of cartilage (C), bone (B), and synovial hyperplasia (S) (right), in comparison
with joints from Cbl-b/ mice (left).
(D) Sera from collagen-IFA immunized mice (n  6) were collected at day 27 after immunization with collagen-IFA and collagen-specific IgG2a
was measured by ELISA.
1993; Gajewski et al., 1994; Wells et al., 2003). T cell It should be noted that our study shows reduced phos-
phorylation of PLC-1 in contrast to enhanced PLC-1anergy can also result in a block in the downstream
signaling events such as activation of the small GTPase degradation as reported previously (Heissmeyer et al.,
2004). The discrepancy between these two studies mayRas or the activation of Erk and JNK (Fields et al., 1996; Li
et al., 1996). The recent discovery of anergy-associated reflect the time frame for the examination of PLC-1:
the change of phosphorylation is more obvious at thegenes suggested that intracellular signaling molecules
are indeed involved in the T cell anergy process, and it early stage of T cell restimulation, as revealed in our
study. Indeed, the observed reduction of PLC-1 phos-was proposed that unbalanced NFAT signaling induces
genes that differ from those induces by the combined phorylation in anergic T cells occurs rapidly after subse-
quent TCR engagement (3–10 min) and coincides withactivation of both NFAT and AP-1 (Macian et al., 2002).
A recent study suggested that the E3 Ub ligase Grail, a the failed Ca2 mobilization, in contrast to the protein
degradation event that happens much later (30 min totransmembrane protein residing in the endosomes, is a
mediator of T cell anergy induction. Grail is only ex- 2 hr, a time frame much later than Ca2 influx) (Heiss-
meyer et al., 2004). Thus, our data provide a more phy-pressed in anergized T cells and might control T cell
unresponsiveness through targeting endocytosis of its siologically relevant model supporting ubiquitination-
dependent modification of signaling molecules in thepotential substrates (Anandasabapathy et al., 2003). Our
study is consistent with a recent study showing that E3 earlier phase of T cell anergy induction.
Our results suggest the following scenario for Cbl-bligases such as Cbl-b, Itch, and Grail were upregulated
during T cell anergy induction, which caused the down- regulated immunotolerance: in response to tolerigenic
signals, Cbl-b expression is selectively induced in aner-modulation of signaling molecules and unstable syn-
apse formation by using in vitro models (Heissmeyer et gic T cells. Cbl-b then participates in T cell tolerance
via promoting ubiquitination of PLC-1 and regulational., 2004). Whether Itch and Grail indeed control immu-
notolerance in vivo needs to be determined. Importantly, of antigen receptor-induced calcium mobilization. Sig-
nificantly, we found that Cbl-b upregulation does notour genetic data on Cbl-b provide in vivo evidence that
an E3 ubiquitin ligase; i.e., Cbl-b, is indeed critically lead to obvious degradation of PLC-1. Instead, Cbl-b
is largely involved in functional modifications (i.e., phos-involved in T cell anergy.
Immunity
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In Vivo Tolerance Modelsphorylation) of PLC-1, most likely via Cbl-b-mediated
To study tolerance of OT-II transgenic CD4 T cells, an adoptiveprotein ubiquitination. It should be noted that Cbl-b
transfer experiment was performed (Bansal-Pakala et al., 2001;plays a more important role for PLC-1 ubiquitination
Kearney et al., 1994). Briefly, Cbl-b/ and Cbl/ OT-II transgenic
in activated and/or tolerized T cells, since Cbl-b does mice were injected intravenously with 500 g of OVA peptide in
not seem to regulate the phosphorylation of PLC-1 in PBS or PBS alone on day 0 and day 3. On day 10, CD4 T cells
were isolated and labeled with CFSE. Cells (Thy1.2V	5, 5 
 105)naive T cells. It therefore appears that increased Cbl-b
were injected into syngeneic B6.Thy1.1 recipients, followed by im-expression resets the activation threshold for antigen
munization with OVA peptide (50 g) in CFA. On day 3, drainingreceptor stimulation. However, this reset must be spe-
lymph node cells were collected, and cells were stained with Thy1.2-cific for at least some defined signaling pathways since
APC and V	5-PE. Thy1.2 cells were gated and CFSE profiles ana-
we only observed PLC-1, but not Akt, hyperphosphory- lyzed on transgenic V	5 cells. Isolated lymph node cells were
lation. Our data provide a novel molecular framework also stimulated in vitro with OVA peptide and irradiated antigen-
presenting cells and cultured for 8 hr. Brefeldin A was added foron the role of ubiquitination-dependent modification of
the last 2 hr. Cells were washed and stained with Thy1.2 APC,signaling molecules in the earlier phase of T cell anergy
followed by intracellular staining with anti-IL-2-PE.induction. Importantly, our results show that the regula-
P14 TCR transgenic mice were intravenously injected with differ-tion of signaling molecules via E3 ligases such as Cbl-b
ent doses of the high-affinity peptide p33, the low-affinity peptide
is critical in setting up and maintaining immunotolerance A4Y, and the wrong peptide AV on day 0, day 3, and in some in-
in vitro and in vivo. stances on day 6 after the initial injection. For detection of prolifera-
tion, T cells were isolated from spleens, and CD8 T cells stimulatedGreat efforts have been made to understand the
in triplicate for different time periods with p33 and AV loaded anti-mechanisms of the peripheral tolerance, since loss of
gen-presenting cells in the presence or absence of recombinantself-tolerance is closely related to the development of
IL-2 and pulsed for the last 16–20 hr with 1 Ci/well 3H-thymidineautoimmune diseases in animal models and humans.
(Amersham). APCs were loaded with 106 M (unless otherwise indi-
However, the pathways leading to tolerance induction cated) of p33 or AV peptide for 1 hr at 37C. 3H-thymidine incorpora-
are not well elucidated. Our data directly link the regula- tion was measured by using a 	-scintillation counter (Coulter). For
induction of superantigen induced tolerance, Cbl-b/ mice weretion of protein ubiquitination to T cell immunotolerance
crossed onto an H2d background and mice injected with 20 g/and clonal anergy in vivo. Intriguingly, in most instances
mouse of SEB (Toxin Technologies). To determine cytokine produc-the outcome of only a single challenge with a recall
tion, sera were harvested and assayed for the production of IL-2,peptide- or superantigen in Cbl-b/ mice is death of
TNF, and IFN by using ELISA (R&D Systems, Minneapolis). Num-
the animal. Thus, Cbl-b-regulated T cell tolerance ap- bers of responding cells and phenotypes of these cells were fol-
pears to be essential for the survival of an animal after lowed by FACS analyses. Single cell suspensions of lymph nodes,
blood ,and spleens were stained with FITC-, PE-, APC-, or biotin-repeated encounters with the same antigen. These data
conjugated Abs reactive to CD3, TCR	, TCRV	6, TCRV	5,also show that the molecular control of antigen receptor
TCRV	8.1/8.2, TCRV2, CD4, CD8, CD25, CD28, CD44, CD69,signaling is an essential component for the maintenance
Thy1.2, and CD62L. Biotinylated Abs were visualized by using strep-of T cell immunotolerance. Moreover, we show here that
tavidin-RED670 (Gibco BRL). Samples were analyzed by flow cytom-
Cbl-b is an important negative regulator of autoimmune etry via a FACScan (Becton Dickinson).
arthritis; ablation of Cbl-b exacerbates the autoimmune
arthritis even in the absence of mycobacterial adjuvant. Biochemistry
Thus, our results might have relevance for novel vaccine Antibodies to Cbl-b (H121), PLC-1 (1249), Ub (8017), and Grb2 (255)
were purchased from Santa Cruz Biotechnology (CA). Anti-PKC,designs and therapeutic interventions in autoimmune
anti-phospho-Akt (Ser493), anti-Vav1 (Tyr174), and anti-Akt (9272)diseases.
Abs were from Cell Signaling (Berverly, MA). The anti-phospho-
PLC-1 (pY783) antibody was from Biosource (Camarillo, CA). CellExperimental Procedures
lysates were subjected to 8%–10% SDS-PAGE and electrotransf-
erred onto polyvinylidene difluoride membranes (Millipore, Bedford,Mice
MA). Immunoblot and ubiquitination assays were performed as de-Two different Cbl-b/ mutant mouse lines (Bachmaier et al., 2000;
scribed (Fang and Liu, 2001). For in vitro Ca2 mobilization, purifiedChiang et al., 2000) were used for the present studies. DBA/1 mice
CD4 T cells were first cultured with ionomycin to induce anergy.and B6.PL-Thy1a (Thy1.1) mice were purchased from the Jackson
Cells were loaded with 1 mM indo-1 for 45 min at 37C. Cells wereLaboratory (Bar Harbor, ME). For the generation of TCR transgenic
then incubated with hamster anti-CD3 for 15 min at 4C. The ratiomice, OVA323-329-specific TCR transgenic OT-II mice were crossed
of indo-1 violet/blue was analyzed by flow cytometry with a BD LSRwith Cbl-b/ mice (Chiang et al., 2000). Moreover, P14 TCR Tg mice
(BD Biosciences, CA). Ca2 mobilization was induced by crosslink-(Pircher et al., 1989) were bred onto the Cbl-b/ (Bachmaier et al.,
ing with rabbit anti-hamster IgG or addition of ionomycin (1 g/ml).2000; Chiang et al., 2000) and Rag2/ backgrounds. Genotyping
Data were analyzed by using FlowJo software (Tree Star, Inc., Sanwas performed by DNA blotting, PCR, and FACS analyses. For Fig-
Carlos, CA).ures 1, 2, 3, and 7, mice generated by Chiang et al. (2000) were
used. For the Figures 2F, 4, 5, and 6, mice generated by Bachmaier
et al. (2000) were used. All mice were housed according to institu- Collagen-Induced Arthritis
tional guidelines. Cbl-b/ mice (Chiang et al., 2000) were backcrossed onto a DBA/1
background to the sixth to eighth generations. Native bovine colla-
gen II (Chondrex, Seattle, MA) was dissolved at 4 mg/ml in 10 mMInduction of Ionomycin-Induced T Cell Anergy In Vitro
For ionomycin-induced anergy, we used a protocol described pre- acetic acid at 4C overnight and emulsified with an equal volume
of CFA or IFA (4 mg/ml each; Chondrex, Seattle, MA). Disease wasviously (Macian et al., 2002) with slight modifications. Naive CD4
T cells were first stimulated with immobilized anti-CD3 (1 g/ml) induced by intradermal injection at the base of the tail with 50 l of
emulsion containing 100 g collagen either in CFA or IFA. On dayplus anti-CD28 (5 g/ml) for two days. The cells were rested for 3
days and then incubated with ionomycin at the indicated concentra- 21, the mice were boosted by intradermal injection with 100 g
collagen in IFA and monitored for signs of arthritis. Clinical arthritistions (Calbiochem). After washing twice with medium, cells were
restimulated with indicated concentrations of anti-CD3 and anti- was assessed by the following scoring system: grade 0, no swelling;
grade 1, mild, but definite redness and swelling of the ankle or wristCD28 for 24–48 hr. Proliferation and IL-2 production were measured
by using 3H-thymidine incorporation and ELISA. or digits; grade 2, moderate redness and swelling of ankle and wrist;
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grade 3, severe redness and swelling of entire paw including digits; sad, K., Gu, H., Liu, Y.C., Dustin, M.L., and Rao, A. (2004). Calcineurin
imposes T cell unresponsiveness through targeted proteolysis ofgrade 4, maximally inflamed limb with involvement of multiple joints.
signaling proteins. Nat. Immunol. 5, 255–265.Each limb was graded, giving a maximum possible score of 16/
mouse. During the development of disease, joints were prepared Joazeiro, C.A., Wing, S.S., Huang, H., Leverson, J.D., Hunter, T.,
for histopathology examination of erosions and synovial infiltrates. and Liu, Y.C. (1999). The tyrosine kinase negative regulator c-Cbl
as a RING-type, E2-dependent ubiquitin-protein ligase. Science
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